RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

This study is testing a new targeted cancer medication called daraxonrasib to see if it works better than standard chemotherapy (docetaxel) for patients with a specific type of lung cancer. The goal is to find more effective ways to treat lung cancer that has spread or cannot be removed by surgery.

You may be eligible if you are 18 or older, active in your daily life, and have a confirmed diagnosis of advanced lung cancer with a specific genetic marker. You must also be in good general health regarding your blood, liver, and kidney function.

If you join, you will be randomly assigned to receive either the new experimental drug or the standard chemotherapy. Doctors will monitor you closely with regular medical scans and health checkups to track how well the treatment is working and ensure your safety.

This study is currently recruiting patients at locations in Birmingham, Alabama; Long Beach, California; and New Haven, Connecticut. Please reach out to your doctor or the study team to see if a center near you is the right fit.